Wednesday, March 17, 2021 11:38:09 AM
PDSB over 75 Million SHARES Traded since February 1st commenced there is about 14 million shares FLOATING. Lock up your shares Good till cancelled months out from today.
42% owned by insiders & institutions.
22 million shares minus shares owned by insiders & tutes
Equals less than 14 million shares Floating 111 million market cap tremendous upside 50x-100x ROI Potential in 2 years.
These MM are spoof trading this stock. Trying to rattle impatient folks. If you do the math there is really no liquid shares out there. They are trying so hard to accumulate this stock. I really believe we will be well into the double digits sooner than later.
The Covid Variant situation in Brazil and South America is spiraling out of control. This vaccine is worth 20 billion or more when approved late next year commercial ready in 2023 emergency EUA could be sooner.
Brazil’s rolling coronavirus disaster is a global problem
https://www.msn.com/en-us/news/world/brazil-e2-80-99s-rolling-coronavirus-disaster-is-a-threat-to-the-world/ar-BB1eFhPN
Bolsonaro’s Standing Craters Amid Historic Health-Care Collapse
https://www.bloombergquint.com/onweb/bolsonaro-s-rejection-soars-amid-historic-healthcare-collapse
PDSB has multi hundred dollar share price potential like NVAX or MRNA
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of PDS0203 with an Award of up to ~US$60 Million
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/501-iotechnnouncesthatits19accineonsortium20210311n
PDSB Website
https://www.pdsbiotech.com/
PDSB March Biz Presentation
https://www.pdsbiotech.com/images/pdf/presentation/2021/march/PDSB_Corporate_Overview_-_March_11_2021_FINAL_1.pdf
PDSB Bleeding edge 2.0 Versamune®-based immunotherapies. technology for Cancer & infectious diseases This is a multibillion possibly double digit billion market cap in the making in the next 12-24 months buy and hold LONG TERM.
$PDSB
Recent PDSB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:33:38 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 09:31:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:10:16 PM
- PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 01/22/2024 09:45:19 PM
- PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/04/2023 09:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:02:38 PM
- PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer • GlobeNewswire Inc. • 11/28/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 11:02:46 AM
- PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 12:30:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:07:59 PM
- PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 08:06:44 PM
- PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO • GlobeNewswire Inc. • 10/23/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 08:02:24 PM
- PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 08:03:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2023 01:02:10 PM
- PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) • GlobeNewswire Inc. • 10/03/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 08:05:34 PM
- PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) • GlobeNewswire Inc. • 10/02/2023 12:00:00 PM
- PDS Biotech to Present at the LD Micro Main Event XVI • GlobeNewswire Inc. • 09/26/2023 12:00:00 PM
- PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 • GlobeNewswire Inc. • 09/25/2023 12:00:13 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM